Journal Home
Search for

Volume 113, Issue 2, Pages 123-128 (September 2009)


View previous. 2 of 32 View next.

Assessing the impact of cannabis use on trends in diagnosed schizophrenia in the United Kingdom from 1996 to 2005

Martin FrisheraCorresponding Author Informationemail address, Ilana Cromebemail address, Orsolina Martinoaemail address, Peter Croftcemail address

Received 17 April 2009; received in revised form 27 May 2009; accepted 30 May 2009. published online 29 June 2009.

Abstract 

A recent systematic review concluded that cannabis use increases risk of psychotic outcomes independently of confounding and transient intoxication effects. Furthermore, a model of the association between cannabis use and schizophrenia indicated that the incidence and prevalence of schizophrenia would increase from 1990 onwards. The model is based on three factors: a) increased relative risk of psychotic outcomes for frequent cannabis users compared to those who have never used cannabis between 1.8 and 3.1, b) a substantial rise in UK cannabis use from the mid-1970s and c) elevated risk of 20 years from first use of cannabis. This paper investigates whether this has occurred in the UK by examining trends in the annual prevalence and incidence of schizophrenia and psychoses, as measured by diagnosed cases from 1996 to 2005. Retrospective analysis of the General Practice Research Database (GPRD) was conducted for 183 practices in England, Wales, Scotland and Northern Ireland. The study cohort comprised almost 600,000 patients each year, representing approximately 2.3% of the UK population aged 16 to 44. Between 1996 and 2005 the incidence and prevalence of schizophrenia and psychoses were either stable or declining. Explanations other than a genuine stability or decline were considered, but appeared less plausible. In conclusion, this study did not find any evidence of increasing schizophrenia or psychoses in the general population from 1996 to 2005.

a Department of Medicines Management, Keele University, Staffordshire, ST5 5BG, United Kingdom

b Academic Psychiatry Unit, Keele University Medical School, Harplands Hospital, Hilton Road, Staffordshire, ST6 4TH, United Kingdom

c Primary Care Sciences Research Centre, Keele University, Staffordshire, ST5 5BG, United Kingdom

Corresponding Author InformationCorresponding author. Tel.: +44 1782 733568; fax: +44 1782 713 586.

PII: S0920-9964(09)00269-2

doi:10.1016/j.schres.2009.05.031


View previous. 2 of 32 View next.